Biosimilar production in Malaysia

Biosimilars/News | Posted 25/09/2015 post-comment2 Post your comment

Malaysian biotech firm Inno Bio Ventures has announced the signing of a memorandum of understanding (MoU) with Iranian firm Aryogen Biopharma. The agreement will lead to the production of the first Malaysian-made biosimilars for the local and regional market.

picture 142

Inno Bio Ventures says that the two companies will now have exclusive rights to market four products across the Asean region, which includes Cambodia, Laos, Myanmar, the Philippines and Vietnam.

The following four products are reported to be involved in the MoU: etanercept; rituximab; trastuzumab and factor VII for haemophilia and congenital factor VII deficiency.

Biosimilars, dominated by global pharma players, have been forecast to expand at a compounded average growth rate of 12% in Asia to an estimated eight billion Malaysian Ringgit (equivalent to Euros 1.65 billion) in the Southeast Asian region by 2020 [1]. Generics manufacturing, prescribing and sales are becoming firmly part of the scene in Malaysia [2].

The Iranian pharmaceutical industry was last mentioned in GaBI Online in 2013, when Professor Abdol Majid Cheraghali*, wrote that Iran’s pharmaceutical industry did not have access to the production procedures of originators, including cell type, fermentation and purification procedures. For this reason, said Cheraghali, Professor of Pharmacology and Toxicology at the University of Baqiyatallah Medical Sciences, Tehran, Iran, companies could not claim ‘similarity’ to originator brands [3].

Copied biopharmaceuticals including granulocyte colony-stimulating factors, human growth hormones and interferons may have received marketing authorization for the local Iranian market, but – at that time – none had received evaluation according to internationally recognized guidelines for biosimilars.

*Professor Abdol Majid Cheragali is a member of the International Editorial Advisory Board of GaBI Journal.

References
1. GaBI Online - Generics and Biosimilars Initiative. Asian companies venture into biosimilars for kidney failure [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Sep 25]. Available from: www.gabionline.net/Biosimilars/News/Asian-companies-venture-into-biosimilars-for-kidney-failure
2. GaBI Online - Generics and Biosimilars Initiative. Generics have their feet under the table in Malaysia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Sep 25]. Available from: www.gabionline.net/Generics/General/Generics-have-their-feet-under-the-table-in-Malaysia
3. Current status of biopharmaceuticals in Iran’s pharmaceutical market. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1).26-9. doi:10.5639/gabij.2013.0201.008 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Inno Bio Ventures, The Star

comment icon Comments (2)
Post your comment
Posted 10/11/2015 by Julie S, GaBI Online Editorial Office
Response to 'Creative Peptides'

Dear Sirs,
Thank you for your interesting comment on this article. We appreciate that you are sharing your thoughts on this subject with us. Please feel free to reach us at editorial@gabi-journal.net with any more of your thoughts. Thank you again and we hope to hear from you soon.

Posted 22/10/2015 by Creative Peptides
Comment

The medical market is becoming wider and wider. I think most developing countries should stress the development of biotech, just like Malaysia. Health issues are always the public concerns.

Related content
Canada approves adalimumab and bevacizumab biosimilars
Health Canada V13I20
Biosimilars/News Posted 22/10/2021
EMA recommends approval of two adalimumab biosimilars
ST002293
Biosimilars/News Posted 01/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010